Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > ASCO June 2023

<< Previous

Bullboard Posts

Next >>

Comment by Trogarzonon Apr 30, 2023 2:46pm

87 Views

Post# 35421756

RE:RE:RE:ASCO June 2023

I'm disgrunted with the company and with it's shareholders now because we're all like hey we're all going to be alright.. trust life. In my book they are past that time, it's game over for the board and for our dedicated management. I'm hiring Remax.

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China